Design and synthesis of novel N-methyl-N-(2,4,6-trimethoxybenzyl)cinnamamide derivatives as CrtN inhibitors for treatment of infectious diseases

Chambers, 2009, Waves of resistance: staphylococcus aureus in the antibiotic era, Nat. Rev. Microbiol., 7, 629, 10.1038/nrmicro2200 Graffunder, 2002, Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials, J. Antimicrob. Chemother., 49, 999, 10.1093/jac/dkf009 Grundmann, 2002, Risk factors for the transmission of methicillin-resistant Staphylococcus aureus in an adult intensive care unit: fitting a model to the data, J Infect Dis, 185, 481, 10.1086/338568 Fischbach, 2009, Antibiotics for emerging pathogens, Science, 325, 1089, 10.1126/science.1176667 Jevons, 1961, “Celbenin”-resistant Staphylococci, Br. Med. J., 1, 124, 10.1136/bmj.1.5219.124-a Payne, 2007, Drugs for bad bugs: confronting the challenges of antibacterial discovery, Nat. Rev. Drug Discov., 6, 29, 10.1038/nrd2201 David, 2008, What is communityassociated methicillin-resistant Staphylococcus aureus?, J Infect Dis, 197, 1235, 10.1086/533502 Melo-Cristino, 2013, First case of infection with vancomycin-resistant Staphylococcus aureus in Europe, Lancet, 382, 205, 10.1016/S0140-6736(13)61219-2 Shallcross, L. J.; Howard, S. J.; Fowler, T.; Davies, S. C. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos. Trans. R. Soc., B 2015, 370, 20140082. Russo, 2015, Linezolid-resistant staphylococcal bacteraemia: A multicentre case-case-control study in Italy, Int. J. Int. J. Antimicrob. Agents, 45, 255, 10.1016/j.ijantimicag.2014.12.008 Rossi, 2014, Transferable vancomycin resistance in a community-associated MRSA lineage, N. Engl. J. Med., 370, 1524, 10.1056/NEJMoa1303359 World Health Organization. Antimicrobial resistance global report on surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 2014. Centers for Disease Control and Prevention. Antibiotic resistance: the global threat (US). http://stacks.cdc.gov/view/cdc/31340. Accessed February 27, 2015. Casadevall, 1999, Host-Pathogen Interactions: Redefining the Basic Concepts of Virulenlence and Pathogenicity, Infect. Immun., 67, 3703, 10.1128/IAI.67.8.3703-3713.1999 Clauditz, 2006, Staphyloxanthin Plays a Role in the Fitness of Staphylococcus aureus and Its Ability to Cope with Oxidative Stress, Infect. Immun., 74, 4950, 10.1128/IAI.00204-06 Wang, 2007, Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice, Nat. Med., 13, 1510, 10.1038/nm1656 Clatworthy, 2007, Targeting virulence: a new paradigm for antimicrobial therapy, Nat. Chem. Biol., 3, 541, 10.1038/nchembio.2007.24 Russo, 2016, Important complexities of the anti-virulence target paradigm: a novel ostensibly resistance-avoiding approach for treating infections, J Infect Dis, 213, 901, 10.1093/infdis/jiv533 Liu, 2005, Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity, J. Exp. Med., 202, 209, 10.1084/jem.20050846 Liu, 2009, Color me bad: microbial pigments as virulence factors, Trends Microbiol., 17, 406, 10.1016/j.tim.2009.06.006 Rasko, 2010, Anti-virulence strategies to combat bacteria-mediated disease, Nat. Rev. Drug Discov., 9, 117, 10.1038/nrd3013 Leejae, 2013, Inhibition of staphyloxanthin biosynthesis in Staphylococcus aureus by rhodomyrtone, a novel antibiotic candidate, J. Med. Microbiol., 62, 421, 10.1099/jmm.0.047316-0 Kuroda, 2007, Sesquiterpene farnesol inhibits recycling of the C55 lipid carrier of the murein monomer precursor contributing to increased susceptibility to β-lactams in methicillinresistant Staphylococcus aureus, J. Antimicrob. Chemother., 59, 425, 10.1093/jac/dkl519 Chen, 2016, Small molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence, Nat. Chem. Biol., 12, 174, 10.1038/nchembio.2003 Song, 2009, Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in staphylococcus aureus, J. Med. Chem., 52, 976, 10.1021/jm801023u Hammond, 1970, Inhibition of vitamin K2 and carotenoid synthesis in Staphylococcus aureus by diphenylamine, J. Bacteriol., 103, 611, 10.1128/jb.103.3.611-615.1970 Raisig, 2001, Functional properties of diapophytoene and related desaturases of C(30) and C(40) carotenoid biosynthetic pathways, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1533, 164, 10.1016/S1388-1981(01)00154-8 Li, 2018, Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity, J. Med. Chem., 61, 224, 10.1021/acs.jmedchem.7b01300 Wang, 2016, Discovery of benzocycloalkane derivatives efficiently blocking bacterial virulence for the treatment of methicillin-resistant S. aureus (MRSA) infections by targeting diapophytoene desaturase (CrtN), J. Med. Chem., 59, 4831, 10.1021/acs.jmedchem.6b00122 Wang, 2016, Discovery of potent benzofuran-derived diapophytoene desaturase (CrtN) inhibitors with enhanced oral bioavailability for the treatment of methicillin-resistant staphylococcus aureus (MRSA) infections, J. Med. Chem., 59, 3215, 10.1021/acs.jmedchem.5b01984 Ni, 2017, Novel Inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus methicillin-resistant, linezolid-resistant, and vancomycin-intermediate staphylococcus aureus infections in vivo, J. Med. Chem., 60, 8145, 10.1021/acs.jmedchem.7b00949 Wei, 2018, Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections, Eur. J. Med. Chem., 145, 235, 10.1016/j.ejmech.2017.12.090 Ni, 2018, Novel staphyloxanthin inhibitors with improved potency against multidrug resistant staphylococcus aureus, ACS Med. Chem. Lett., 9, 233, 10.1021/acsmedchemlett.7b00501 Ni, 2020, Targeting virulence factors as an antimicrobial approach: pigment inhibitors, Med. Res. Rev., 40, 293, 10.1002/med.21621 Singh, 2009, Phloroglucinol compounds of therapeutic interest: global patent and technology status, Expert Opin. Ther. Pat., 19, 847, 10.1517/13543770902916614 Pal Singh, 2006, Phloroglucinol compounds of natural origin, Nat. Prod. Rep., 23, 558, 10.1039/b600518g Javed, 2021, Pharmacological applications of phlorotannins: a comprehensive review, Curr. Drug Discov. Technol., 18, 282, 10.2174/1570163817666200206110243